Dr. Julian Falutz
Biography & Research Background
Julian Falutz, MD, is affiliated with the Montreal General Hospital and McGill University Health Centre. He serves as lead author on the pivotal multicenter Phase 3 clinical trials and pooled tolerability analyses that established Tesamorelin's efficacy in reducing visceral adipose tissue in HIV-infected study subjects. His work was central to the FDA approval of Egrifta. Julian Falutz is being referenced as one of the leading scientists involved in the research and development of Tesamorelin. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Authored Research Profiles (1)
Dr. Julian Falutz is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
Dr. Julian Falutz is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.